Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | PRCP | P42785 | 4/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL745670 | 0.89 | OPRL1 (0.51) | ACHE | |
| SCHEMBL2880360 | 0.73 | OPRL1 (0.60) | SIGMAR1DRD2 | |
| SCHEMBL83703 | 0.72 | SIGMAR1 (0.49) | SIGMAR1DRD2 | |
| SCHEMBL6649554 | 0.72 | OPRL1 (0.56) | SIGMAR1 | |
| SCHEMBL9373500 | 0.71 | SLC6A3 (0.54) | SIGMAR1DRD2ACHE | |
| SCHEMBL8097585 | 0.71 | SIGMAR1 (0.82) | SIGMAR1DRD2 | |
| SCHEMBL8099056 | 0.70 | SIGMAR1 (0.67) | SIGMAR1DRD2 | |
| SCHEMBL6967833 | 0.69 | OPRL1 (0.56) | DRD2 | |
| SCHEMBL25357912 | 0.69 | OPRL1 (0.52) | SIGMAR1ACHE | |
| SCHEMBL11197820 | 0.69 | OPRL1 (0.46) | SIGMAR1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102439008-A | 1,2, 3-triazolo [4,3-a ] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders | ORTHO MCNEIL JANSSEN PHARM | 2012-05-02 | — | — | CN | disclosed |